Supplemental table 4. First-line treatment and country of origin stratified to ethnicity.

|  |  |  |  |
| --- | --- | --- | --- |
|  | WhiteN=29 | Non-whiteN=38 | P valuea |
| First-line treatment, n (%) |  |  |  |
| Azathioprine | 14/35 (40) | 21/35 (60) | 0.627 |
| Mycophenolate  | 6/10 (60) | 4/10 (40) | 0.309 |
| Rituximab | 6/14 (42.9) | 8/14 (57.1) | >0.999 |
| Other treatment/No treatment | 3/8 (37.5) | 5/8 (62.5) | 0.567 |
| Country of origin, n (%) |  |  |  |
| Brazil | 7 /20 (35) | 13/20 (65) | 0.428 |
| United Kingdom | 5/18 (27.8) | 13/18 (72.2) | 0.167 |
| France | 2/10 (20)  | 8/10 | 0.168 |
| Spain | 5/6 (83.3) | 1/6 (16.7) | 0.078 |
| Germany/Austria | 3/5 (60) | 2/5 (40) | 0.645 |
| Other countries | 7/8 (87.5) | 1/8 (12.5) | 0.017 |

aFisher test.